NEW YORK — Dutch diagnostics firm SkylineDx said on Monday that it has received a €20 million ($21.9 million) investment to further develop its melanoma test.
The funding is being provided by private investor Aat van Herk, and will be used to perform clinical testing of an assay — developed in collaboration with the Mayo Clinic — designed to predict the risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.
In June, SkylineDx received accreditation from the College of American Pathologists following the CLIA certification of its San Diego laboratory.